CARLSBAD, Calif., June 18, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) under which Otsuka obtains exclusive rights across the Asia-Pacific region for donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Ionis will maintain primary responsibility for the development of donidalorsen, while Otsuka will be responsible for territory-specific development, regulatory filings and commercialization in the Asia-Pacific region and Europe.
Otsuka backs Bradley Cooper-produced doc film about caregivers
Otsuka and Lundbeck’s atypical antipsychotic Rexulti has taken the crown away from AbbVie as the largest TV drug ad spender in April, according to the latest data out from real-time ad trackers iSpot.TV.
Notice Concerning Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation
Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
The European Commission (EC) has approved Otsuka Pharmaceutical Europe and H Lundbeck’s Abilify Maintena 720mg/960mg (aripiprazole) for the maintenance treatment of schizophrenia.
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease
Otsuka and Sumitomo Revise License Agreement
Otsuka Submits New Drug Application in Japan for Voclosporin